Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids

被引：0
|
作者：
Talaulikar, Vikram Sinai [1 ]
Manyonda, Isaac [1 ]
机构：
[1] St Georges Hosp & Univ London, London SW17 0RE, England
来源：
WOMENS HEALTH | 2014年 / 10卷 / 06期
关键词：
fibroids; medical; myoma; SPRM; ulipristal acetate;
D O I：
10.2217/WHE.14.60
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Although it has been known for a long time that uterine fibroids respond to changes in sex steroid concentrations, it is the availability of selective progesterone receptor modulators such as ulipristal acetete that has provided the gynecologist with a novel option for medical management of uterine fibroids. Ulipristal acetate is presently licensed in Europe for use in women with symptomatic fibroids up to 3 months prior to surgery and has demonstrated good clinical efficacy and safety for this indication. Future trials will define the long-term safety of this drug and its role in medical management of uterine fibroids.
引用
收藏
页码：565 / 570
页数：6
相关论文
共 50 条
  • [31] Long-term treatment of uterine fibroids with ulipristal acetate
    Donnez, Jacques
    Vazquez, Francisco
    Tomaszewski, Janusz
    Nouri, Kazem
    Bouchard, Philippe
    Fauser, Bart C. J. M.
    Barlow, David H.
    Palacios, Santiago
    Donnez, Olivier
    Bestel, Elke
    Osterloh, Ian
    Loumaye, Ernest
    FERTILITY AND STERILITY, 2014, 101 (06) : 1565 - U405
  • [32] Treatment of Symptomatic Uterine Fibroids with Ulipristal Acetate: Endometrial Safety
    Catherino, William
    Eisenhut, Carol
    Blakesley, Rick
    Chan, Anna
    Sniukiene, Vilma
    Goldstein, Steven
    LABORATORY INVESTIGATION, 2017, 97 : 279A - 279A
  • [33] COST-UTILITY ANALYSIS OF ULIPRISTAL ACETATE (5 MG) FOR LONG-TERM TPIH23 REATMENT OF MODERATE TO SEVERE SYMPTOMS OF UTERINE FIBROIDS IN PORTUGAL
    Paquete, A.
    Lehmann, M.
    Silva, D. P.
    Pinto, C. G.
    VALUE IN HEALTH, 2016, 19 (07) : A403 - A403
  • [34] Ulipristal AcetateIn Uterine Fibroids
    Jamie D. Croxtall
    Drugs, 2012, 72 : 1075 - 1085
  • [35] Ulipristal Acetate: a Novel Option for the Medical Management of Symptomatic Uterine Fibroids
    Talaulikar, Vikram S.
    Manyonda, Isaac T.
    ADVANCES IN THERAPY, 2012, 29 (08) : 655 - 663
  • [36] Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France
    Fernandez, Herve
    Jourdain, Olivier
    Villefranque, Vincent
    Lehmann, Matthieu
    Lafuma, Antoine
    Trancart, Matthieu
    BMJ OPEN, 2017, 7 (09):
  • [37] The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids
    Bouchard, Philippe
    Chabbert-Buffet, Nathalie
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2017, 40 : 105 - 110
  • [38] Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues
    Perez-Lopez, F. R.
    CLIMACTERIC, 2015, 18 (02) : 177 - 181
  • [39] Repeated-intermittent use of ulipristal acetate for the management of uterine fibroids: an Italian pharmacoeconomic evaluation
    Maratea, Dario
    MINERVA GINECOLOGICA, 2016, 68 (01): : 15 - 20
  • [40] Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review
    De Gasperis-Brigante, Cassandra
    Singh, Sukhbir S.
    Vilos, George
    Kives, Sari
    Murji, Ally
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2018, 40 (08) : 1066 - +
12345